Graybug Vision

Graybug Vision, Inc. develops ophthalmic drugs. It focus on developing drug delivery therapies for the treatment of eye diseases such as age-related macular degeneration and glaucoma. The company was founded by Justin S. Hanes, Peter John McDonnell, Christy Wyskiel and Peter A. Campochiaro in May 2011 and is headquartered in Redwood City, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CalciMedica, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for life-threatening inflammatory diseases. The firm's product candidate Auxora helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.

REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its trading symbol to “CALC.” The Company's common stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol “CALC.” The name and trading symbol change were undertaken in connection with the previously announced merger between Graybug and CalciMedica, Inc. (CalciMedica).

Graybug Announces Name and Trading Symbol Change

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Graybug Vision, Inc. (NasdaqGM: GRAY) with CalciMedica Inc. pursuant to which Graybug shareholders will end up owning just 29% of the combined company, subject to certain adjustments.

GRAYBUG VISION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graybug Vision, Inc. - GRAY

Apollo Endosurgery

Imago Biosciences

Salisbury Bancorp

NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Imago BioSciences, Inc. (NASDAQ: IMGO)'s  sale to Merck for $36.00 per share in cash. If you are an Imago shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, GRAY, APEN, SAL

New York, New York--(Newsfile Corp. - December 5, 2022) -  Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Graybug Vision, Inc. (NASDAQ: GRAY), relating to its proposed merger with CalciMedica Inc.

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Graybug Vision, Inc. - GRAY

MILWAUKEE , Nov. 22, 2022 /PRNewswire/ -- Ademi LLP is investigating Graybug (Nasdaq: GRAY) for possible breaches of fiduciary duty and other violations of law in its transaction with CalciMedica.  Click here to learn how to join the action https://www.ademilaw.com/case/graybug-vision-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Graybug Vision, Inc. has entered into a Fair Transaction with CalciMedica

NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Graybug Vision, Inc. (NASDAQ: GRAY) and CalciMedica Inc. is fair to Graybug shareholders.

GRAY STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Graybug Vision, Inc. Is Fair to Shareholders

– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases

Graybug and CalciMedica Enter into Definitive Merger Agreement

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022.

Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022.

Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments

BARK

Revelation Biosciences

Reviva Pharmaceuticals

Hot penny stocks to watch this week. The post Penny Stocks To Watch: Why REVB, RVPH, BARK, and GRAY Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why REVB, RVPH, BARK, and GRAY Stock Are Moving

BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming Ophthalmology Innovation Source (OIS) Retina Innovation Summit, to be held in New York City on July 13, 2022.

Graybug to Present at the 2022 OIS Retina Innovation Summit

Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.

Graybug (GRAY) to Review Strategic Alternatives, Stock Up

Today, investors in Graybug Vision and GRAY stock are cheering an announced strategic review, which could see a sale of the company. The post Graybug Vision (GRAY) Stock Soars 35% on Strategic Review News appeared first on InvestorPlace.

Graybug Vision (GRAY) Stock Soars 35% on Strategic Review News

HTG Molecular Diagnostics

Smart for Life Inc

Alaunos Therapeutics

Vallon Pharmaceuticals

Penny stocks to watch right now. The post Best Penny Stocks For July 2022?

Best Penny Stocks For July 2022? 5 To Watch Right Now

BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that its Board of Directors will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.

Graybug Announces Review of Strategic Alternatives

BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug Vision, will present an update on the clinical development plan for GB-102 in wet age-related macular degeneration, and will be part of a subsequent panel discussion at the upcoming Clinical Trials at the Summit Meeting, to be held in person at the Hyatt Regency Lake Tahoe in Nevada, as well as virtually, on May 21, 2022.

Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting

BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 2022.

Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting

BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, to be held in Washington, D.C. from April 22-26, 2022.

Graybug to Present at the 2022 ASCRS Annual Meeting

BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Directors, effective April 13, 2022. Dr. Sauer will serve as a member of the Nomination and Corporate Governance Committee of the Board. He will also chair the Science and Innovation Committee, the purpose of which is to advise the Board on the company's research and development as well as clinical manufacturing and control strategies.

Graybug Vision Appoints Dirk Sauer to Board of Directors

BALTIMORE, March 30, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a strategic update on its pipeline programs GB-102 in wet age-related macular degeneration (wet AMD), GB-401 in primary open-angle glaucoma (POAG), as well as its newly acquired assets in corneal disease (GB-501), inherited retinal diseases (GB-601), and geographic atrophy (GB-701).

Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023

BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that it will host a virtual Investor R&D Day from 11 a.m. - 12:45 p.m. ET on March 30, 2022.

Graybug Vision to Host Virtual R&D Day on March 30, 2022

Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET

Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments

BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced its participation in three upcoming medical and investor conferences:

Graybug to Participate in Three Upcoming Medical and Investor Conferences

BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced the hiring of six new employees who will enhance Graybug's Research & Development (R&D), Regulatory Affairs and Program Management capabilities, as the Company further builds momentum behind its pipeline in 2022.

Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline

BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and nine months ended September 30, 2021.

News for Graybug Vision Stock (GRAY)